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A case of palliative urethral stenting for canine prostatic carcinoma tumors and malignant urethral obstruction in cats has been reported［11, 12, 16］ .
In the present study, prostatic cancer was diagnosed in a dog with stranguria and dysuria, and urethral dilatation was performed using a urethral stent. Dysuria improved immediately after urethral stenting, enabling natural urination and maintenance of good quality of life（QOL）until the dog died after 3 months. (5) were measured on X-ray images. Fig. 2-4．Urethral longitudinal section. Urethral diameter ⑷ was confirmed on ultrasonographic imaging. Distance ⑶ from the tumor in the bladder trigone ⑴ to the prostatic urethra ⑵ was 43 mm. This distance was extended by each cranial and caudal about 10mm using a 60-mm stent. Transverse diameter was initially 4 mm ⑷ and became 5.4 mm on dilatation ⑸ , representing a 10% increase. A stent thickness of 6 mm was selected. Since urethral reobstruction due to growth of the prostatic cancer and infiltration into the urethral stent was suggested, chemotherapy using mitoxantrone was added. No findings, such as urethral obstruction or distal metastasis due to the tumor, or cancerous peritonitis, were found up to the time of death, but the dog died on day 99 of the illness due to progression of cancerous cachexia, including marked weight loss and anorexia. However, natural urination was possible and good QOL was maintained thanks to urethral dilatation using a urethral stent at an early stage, confirming that urethral stents are minimally invasive in the body and allow long-term urination control. This approach appears to be useful as a palliative therapy for malignant tumors associated with urethral obstruction.
The dog was a 9-year-old castrated male

